Antiretroviral Drug Profiles

Home > Treatment > Drugs

Susa Coffey, MD, University of California San Francisco

Nucleoside/Nucleotide Analogues

Nonnucleoside Reverse Transcriptase Inhibitors

Protease Inhibitors

Fusion Inhibitors

Chemokine Coreceptor Antagonists

Integrase Inhibitors

Related Resources

About ARV Drugs

DHHS Guidelines

When to Start Treatment

Risks and Benefits of Therapy at CD4 > 350

ARV Therapy for Treatment Naive Patients

Advantages and Disadvantages of Initial Therapy Components

Not Recommended as Initial Therapy

Should Not be Offered at Any Time

Adverse Events of ARVs

Dosage Adjustments for ARV-ARV Drug Interactions (Adult Dosing)

Interactions Database

Stanford Resistance Figures/Notes

Nucleoside/Nucleotide Analogues

		Abacavir (Ziagen, ABC)

		Didanosine (Videx, ddI)

		Emtricitabine (Emtriva, FTC)

		Lamivudine (Epivir, 3TC)

		Stavudine (Zerit, d4T)

		Tenofovir (Viread, TDF)

		Zalcitabine (Hivid, ddC) Discontinued by manufacturer 12/31/06

		Zidovudine (Retrovir, AZT, ZDV)

Nonnucleoside Reverse Transcriptase Inhibitors

		Delavirdine (Rescriptor, DLV)

		Efavirenz (Sustiva, Stocrin, EFV)

		Etravirine (Intelence, TMC 125)

		Nevirapine (Viramune, NVP)

Protease Inhibitors

		Amprenavir (Agenerase, APV) Discontinued by manufacturer 10/07

		Atazanavir (Reyataz, ATV)

		Darunavir (Prezista, DRV, TMC 114)

		Fosamprenavir (Lexiva, Telzir, FPV)

		Indinavir (Crixivan, IDV)

		Lopinavir/Ritonavir (Kaletra)

		Nelfinavir (Viracept, NFV)

		Ritonavir (Norvir, RTV)

		Saquinavir (Invirase, SQV)

		Tipranavir (Aptivus, TPV)

Fusion Inhibitors

		Enfuvirtide (Fuzeon, ENF, T-20)

Chemokine Coreceptor Antagonists

		Maraviroc (Selzentry, Celsentri, MVC)

Integrase Inhibitors

		Raltegravir (Isentress, RAL)

|

|

|

|

|

|

UCSF - Center for HIV Information

HIV InSite is a project of the UCSF Center for HIV Information. Copyright 2008, Regents of the University of California.